“Hot Flash” Persistence At Week 12 Suggests Cool Reception For Products At FDA Cmte
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory Committee for Reproductive Health Drugs will consider efficacy of Depomed’s and Noven Therapeutics’ vasomotor symptom treatments, but both had problems maintaining their effects at week 12 of clinical trials.